Regulation of inflammation and proliferation of human bladder carcinoma cells by type-1 and type-2 cannabinoid receptors

Life Sciences

Volumn 138, Issue , 2015, Pages 41-51

  Gasperi, Valeria ^a   Evangelista, Daniela ^a   Oddi, Sergio ^b,c   Florenzano, Fulvio ^d   Chiurchiù, Valerio ^c,e   Avigliano, Luciana ^a   Catani, M Valeria ^a   Maccarrone, Mauro ^c,e  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

^b UNIVERSITY OF TERAMO   (Italy)

^c IRCCS FONDAZIONE SANTA LUCIA   (Italy)

^d EUROPEAN BRAIN RESEARCH INSTITUTE   (Italy)

^e UNIVERSITY CAMPUS BIO MEDICO   (Italy)

Author keywords

Cancer; Cannabinoid receptors; Endocannabinoids; Inflammation; Proliferation

Indexed keywords

1 (2,4 DICHLOROPHENYL) 5 (4 IODOPHENYL) 4 METHYL N MORPHOLINO 1H PYRAZOLE 3 CARBOXAMIDE; 2 ARACHIDONOYLGLYCEROL; CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; PADGEM PROTEIN; TUMOR NECROSIS FACTOR ALPHA; CANNABINOID; L SELECTIN;

ARTICLE; BLADDER CARCINOMA; CARCINOMA CELL; CARCINOMA CELL LINE; CELL ADHESION; CELL CYCLE; CELL CYCLE PROGRESSION; CELL DEATH; CELL INTERACTION; CELL PROLIFERATION; CONTROLLED STUDY; CYTOKINE RELEASE; ENZYME LINKED IMMUNOSORBENT ASSAY; FLUORESCENCE ACTIVATED CELL SORTING; HUMAN; HUMAN CELL; IN VITRO STUDY; INFLAMMATION; T LYMPHOCYTE; BLADDER TUMOR; DRUG EFFECTS; JURKAT CELL LINE; METABOLISM; PATHOLOGY; TUMOR CELL LINE;

CANNABINOIDS; CELL DEATH; CELL LINE, TUMOR; CELL PROLIFERATION; HUMANS; INFLAMMATION; JURKAT CELLS; L-SELECTIN; RECEPTOR, CANNABINOID, CB1; RECEPTOR, CANNABINOID, CB2; TUMOR NECROSIS FACTOR-ALPHA; URINARY BLADDER NEOPLASMS;

EID: 84940467113     PISSN: 00243205     EISSN: 18790631     Source Type: Journal    
DOI: 10.1016/j.lfs.2014.09.031     Document Type: Article

References (66)

1. B. Adinolfi, A. Romanini, A. Vanni, E. Martinotti, A. Chicca, S. Fogli, and et al. Anticancer activity of anandamide in human cutaneous melanoma cells Eur J Pharmacol 718 2013 154 159
2. A. Alexander, P.F. Smith, and R.J. Rosengren Cannabinoids in the treatment of cancer Cancer Lett 285 2009 6 12
3. F. Balkwill Tumour necrosis factor and cancer Nat Rev Cancer 9 2009 361 371
4. F. Balkwill, and A. Mantovani Inflammation and cancer: back to Virchow? Lancet 357 2001 539 545
5. A. Ben-Baruch The multifaceted roles of chemokines in malignancy Cancer Metastasis Rev 25 2006 357 371
6. E.V. Berdyshev, E. Boichot, N. Germain, N. Allain, J.P. Anger, and V. Lagente Influence of fatty acid ethanolamides and delta9-tetrahydrocannabinol on cytokine and arachidonate release by mononuclear cells Eur J Pharmacol 330 1997 231 240
7. M. Bifulco, C. Laezza, M. Valenti, A. Ligresti, G. Portella, and V. Di Marzo A new strategy to block tumor growth by inhibiting endocannabinoid inactivation FASEB J 18 2004 1606 1608
8. M. Bifulco, C. Laezza, S. Pisanti, and P. Gazzerro Cannabinoids and cancer: pros and cons of an antitumour strategy Br J Pharmacol 148 2006 123 135
9. C. Blázquez, A. Carracedo, L. Barrado, P.J. Real, J.L. Fernández-Luna, G. Velasco, and et al. Cannabinoid receptors as novel targets for the treatment of melanoma FASEB J 20 2006 2633 2635
10. C.S. Breivogel, D.E. Selley, and S.R. Childers Cannabinoid receptor agonist efficacy for stimulating [35S]GTPγS binding to rat cerebellar membranes correlates with agonist-induced decreases in GDP affinity J Biol Chem 273 1998 16865 16873
11. I. Brown, M.G. Cascio, D. Rotondo, R.G. Pertwee, S.D. Heys, and K.W. Wahle Cannabinoids and omega-3/6 endocannabinoids as cell death and anticancer modulators Prog Lipid Res 52 2013 80 109
12. T. Cai, G. Nesi, V. Boddi, S. Mazzoli, M. Dal Canto, and R. Bartoletti Prognostic role of the tumor-associated tissue inflammatory reaction in transitional bladder cell carcinoma Oncol Rep 16 2006 329 334
13. A. Carracedo, M. Gironella, M. Lorente, S. Garcia, M. Guzmán, G. Velasco, and et al. Cannabinoids induce apoptosis of pancreatic tumor cells via endoplasmic reticulum stress-related genes Cancer Res 66 2006 6748 6755
14. M.V. Catani, F. Fezza, S. Baldassarri, V. Gasperi, A. Bertoni, N. Pasquariello, and et al. Expression of the endocannabinoid system in the bi-potential HEL cell line: commitment to the megakaryoblastic lineage by 2-arachidonoylglycerol J Mol Med 87 2009 65 74
15. M.V. Catani, V. Gasperi, G. Catanzaro, S. Baldassarri, A. Bertoni, F. Sinigaglia, and et al. Human platelets express authentic CB1 and CB2 receptors Curr Neurovasc Res 7 2010 311 318
16. M.T. Cencioni, V. Chiurchiù, G. Catanzaro, G. Borsellino, G. Bernardi, L. Battistini, and et al. Anandamide suppresses proliferation and cytokine release from primary human T-lymphocytes mainly via CB2 receptors PLoS One 5 2010 e8688
17. E. Cerami, J. Gao, U. Dogrusoz, B.E. Gross, S.O. Sumer, B.A. Aksoy, and et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data Cancer Discov 2 2012 401 404
18. L.M. Coussens, and Z. Werb Inflammation and cancer Nature 420 2002 860 867
19. K. DeSouza, S. Chowdhury, and S. Hughes Prompt diagnosis key in bladder cancer Practitioner 258 2014 23 27
20. V. Di Marzo, and D.G. Deutsch Biochemistry of the endogenous ligands of cannabinoid receptors Neurobiol Dis 5 1998 386 404
21. V. Di Marzo, and A. Szallasi Rimonabant in rats with a metabolic syndrome: good news after the depression Br J Pharmacol 154 2008 915 917
22. D.L. Faustman, and M. Davis TNF receptor 2 and disease: autoimmunity and regenerative medicine Front Immunol 4 2013 478
23. D. Fegley, S. Gaetani, A. Duranti, A. Tontini, M. Mor, G. Tarzia, and et al. Characterization of the fatty acid amide hydrolase inhibitor cyclohexyl carbamic acid 3′-carbamoyl-biphenyl-3-yl ester (URB597): effects on anandamide and oleoylethanolamide deactivation J Pharmacol Exp Ther 313 2005 352 358
24. J. Gao, B.A. Aksoy, U. Dogrusoz, G. Dresdner, B. Gross, S.O. Sumer, and et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal Sci Signal 6 2013 pl1
25. V. Gasperi, D. Evangelista, V. Chiurchiù, F. Florenzano, I. Savini, S. Oddi, and et al. 2-Arachidonoylglycerol modulates human endothelial cell/leukocyte interactions by controlling selectin expression through CB1 and CB2 receptors Int J Biochem Cell Biol 51 2014 79 88
26. S.J. Gatley, R. Lan, N.D. Volkow, N. Pappas, P. King, C.T. Wong, and et al. Imaging the brain marijuana receptor: development of a radioligand that binds to cannabinoid CB1 receptors in vivo J Neurochem 70 1998 417 423
27. P. Gazzerro, A.M. Malfitano, M.C. Proto, A. Santoro, S. Pisanti, M.G. Caruso, and et al. Synergistic inhibition of human colon cancer cell growth by the cannabinoid CB1 receptor antagonist rimonabant and oxaliplatin Oncol Rep 23 2010 171 175
28. M. Guida, A. Ligresti, D. De Filippis, A. D'Amico, S. Petrosino, M. Cipriano, and et al. The levels of the endocannabinoid receptor CB2 and its ligand 2-arachidonoylglycerol are elevated in endometrial carcinoma Endocrinology 151 2010 921 928
29. J. Guindon, and A.G. Hohmann The endocannabinoid system and cancer: therapeutic implication Br J Pharmacol 163 2011 1447 1463
30. K. Gustafsson, B. Christensson, B. Sander, and J. Flygare Cannabinoid receptor-mediated apoptosis induced by R(+)-methanandamide and Win, 55,212-2 is associated with ceramide accumulation and p38 activation in mantle cell lymphoma Mol Pharmacol 70 2006 1612 1620
31. D.J. Hermanson, and L.J. Marnett Cannabinoids, endocannabinoids, and cancer Cancer Metastasis Rev 30 2011 599 612
32. C.J. Hillard, S. Manna, M.J. Greenberg, R. DiCamelli, R.A. Ross, L.A. Stevenson, and et al. Synthesis and characterization of potent and selective agonists of the neuronal cannabinoid receptor (CB1) J Pharmacol Exp Ther 289 1999 1427 1433
33. J.W. Huffman, S. Yu, V. Showalter, M.E. Abood, J.L. Wiley, D.R. Compton, and et al. Synthesis and pharmacology of a very potent cannabinoid lacking a phenolic hydroxyl with high affinity for the CB2 receptor J Med Chem 39 1996 3875 3877
34. T.C. Islam, A.C. Asplund, J.M. Lindvall, L. Nygren, J. Liden, E. Kimby, and et al. High level cannabinoid receptor 1, resistance of regulator G protein signaling 13 and differential expression of Cyclin D1 in mantle cell lymphoma Leukemia 17 2003 1880 1890
35. C. Laezza, A. d'Alessandro, A.M. Malfitano, and M. Bifulco Anandamide inhibits the Wnt/β-catenin signalling pathway in human breast cancer MDA MB 231 cells Eur J Cancer 49 2013 2066 2067
36. G. Landskron, M. De la Fuente, P. Thuwajit, C. Thuwajit, and M.A. Hermoso Chronic inflammation and cytokines in the tumor microenvironment J Immunol Res 2014 2014 149185 10.1155/2014/149185
37. S. Letašiová, A. Medve'ová, A. Šovčíková, M. Dušinská, K. Volkovová, C. Mosoiu, and et al. Bladder cancer, a review of the environmental risk factors Environ Health 11 2012 S11
38. K. Ley The role of selectins in inflammation and disease Trends Mol Med 9 2003 263 268
39. H. Li, J.T. Wood, K.M. Whitten, S.K. Vadivel, S. Seng, A. Makriyannis, and et al. Inhibition of fatty acid amide hydrolase activates Nrf2 signalling and induces heme oxygenase 1 transcription in breast cancer cells Br J Pharmacol 170 2013 489 505
40. J.Z. Long, W. Li, L. Booker, J.J. Burston, S.G. Kinsey, J.E. Schlosburg, and et al. Selective blockade of 2-arachidonoylglycerol hydrolysis produces cannabinoid behavioral effects Nat Chem Biol 5 2009 37 44
41. M. Maccarrone Endocannabinoid signaling in cancer: a rather complex puzzle Trends Pharmacol Sci 34 2013 426 427
42. A.M. Malfitano, C. Laezza, S. Pisanti, P. Gazzerro, and M. Bifulco Rimonabant (SR141716) exerts anti-proliferative and immunomodulatory effects in human peripheral blood mononuclear cells Br J Pharmacol 153 2008 1003 1010
43. A.M. Malfitano, C. Laezza, M. Galgani, G. Matarese, A. D'Alessandro, P. Gazzerro, and et al. The CB1 receptor antagonist rimonabant controls cell viability and ascitic tumour growth in mice Pharmacol Res 65 2012 365 371
44. C.J. Martins, V. Genelhu, V. Di Marzo, and E.A. Francischetti The endocannabinoid system - back to the scene of cardiometabolic risk factors control? Horm Metab Res 46 2014 529 536
45. V. Michalaki, K. Syrigos, P. Charles, and J. Waxman Serum levels of IL-6 and TNF-alpha correlate with clinicopathological features and patient survival in patients with prostate cancer Br J Cancer 90 2004 2312 2316
46. D.S. Michaud Chronic inflammation and bladder cancer Urol Oncol 25 2007 260 268
47. M.B. Mockler, M.J. Conroy, and J. Lysaght Targeting T cell immunometabolism for cancer immunotherapy; understanding the impact of the tumor microenvironment Front Oncol 4 2014 107
48. M. Moussa, Z. Omran, M. Nosseir, A. Lotfy, and T. Swellam Cyclooxygenase-2 expression on urothelial and inflammatory cells of cystoscopic biopsies and urine cytology as a possible predictive marker for bladder carcinoma APMIS 117 2009 45 52
49. K. Nithipatikom, M.P. Endsley, M.A. Isbell, J.R. Falck, Y. Iwamoto, C.J. Hillard, and et al. 2-Arachidonoylglycerol: a novel inhibitor of androgen-independent prostate cancer cell invasion Cancer Res 64 2004 8826 8830
50. G. Ortar, A. Ligresti, L. De Petrocellis, E. Morera, and V. Di Marzo Novel selective and metabolically stable inhibitors of anandamide cellular uptake Biochem Pharmacol 65 2003 1473 1481
51. D.M. Pardoll Spinning molecular immunology into successful immunotherapy Nat Rev Immunol 2 2002 227 238
52. R.G. Pertwee, A.C. Howlett, M.E. Abood, S.P. Alexander, V. Di Marzo, M.R. Elphick, and et al. International Union of Basic and Clinical Pharmacology. LXXIX. Cannabinoid receptors and their ligands: beyond CB1 and CB2 Pharmacol Rev 62 2010 588 631
53. S. Petti Lifestyle risk factors for oral cancer Oral Oncol 45 2009 340 650
54. J. Pfitzenmaier, R. Vessella, C.S. Higano, J.L. Noteboom, D. Wallace Jr., and E. Corey Elevation of cytokine levels in cachectic patients with prostate carcinoma Cancer 97 2003 1211 1216
55. E. Pikarsky, R.M. Porat, I. Stein, R. Abramovitch, S. Amit, S. Kasem, and et al. NF-kappaB functions as a tumour promoter in inflammation-associated cancer Nature 431 2004 4461 4466
56. S. Pisanti, P. Picardi, A. D'Alessandro, C. Laezza, and M. Bifulco The endocannabinoid signaling system in cancer Trends Pharmacol Sci 34 2013 273 282
57. M. Rajesh, P. Mukhopadhyay, S. Bátkai, G. Haskó, L. Liaudet, J.W. Huffman, and et al. CB2-receptor stimulation attenuates TNF-alpha-induced human endothelial cell activation, transendothelial migration of monocytes, and monocyte-endothelial adhesion Am J Physiol Heart Circ Physiol 293 2007 2210 2218
58. J. Ravi, A. Sneh, K. Shilo, M.W. Nasser, and R.K. Ganju FAAH inhibition enhances anandamide mediated anti-tumorigenic effects in non-small cell lung cancer by downregulating the EGF/EGFR pathway Oncotarget 5 2014 2475 2486
59. M. Rinaldi-Carmona, F. Barth, J. Millan, J.M. Derocq, P. Casellas, C. Congy, and et al. SR 144528, the first potent and selective antagonist of the CB2 cannabinoid receptor J Pharmacol Exp Ther 284 1998 644 650
60. D. Sarnataro, S. Pisanti, A. Santoro, P. Gazzerro, A.M. Malfitano, C. Laezza, and et al. The cannabinoid CB1 receptor antagonist rimonabant (SR141716) inhibits human breast cancer cell proliferation through a lipid raft-mediated mechanism Mol Pharmacol 70 2006 1298 1306
61. J.R. Savinainen, S.M. Saario, and J.T. Laitinen The serine hydrolases MAGL, ABHD6 and ABHD12 as guardians of 2-arachidonoylglycerol signalling through cannabinoid receptors Acta Physiol 204 2012 267 276
62. U. Schwab, L. Lauritzen, T. Tholstrup, T. Haldorssoni, U. Riserus, M. Uusitupa, and et al. Effect of the amount and type of dietary fat on cardiometabolic risk factors and risk of developing type 2 diabetes, cardiovascular diseases, and cancer: a systematic review Food Nutr Res 58 2014 10.3402/fnr.v58.25145
63. B.C. Sheu, W.C. Chang, C.Y. Cheng, H.H. Lin, D.Y. Chang, and S.C. Huang Cytokine regulation networks in the cancer microenvironment Front Biosci 13 2008 6255 6268
64. J.E. Talmadge, M. Donkor, and E. Scholar Inflammatory cell infiltration of tumors: Jekyll or Hyde Cancer Metastasis Rev 26 2007 373 400
65. K.H. Toomer, and Z. Chen Autoimmunity as a double agent in tumor killing and cancer promotion Front Immunol 5 2014 116 10.3389/fimmu.2014.00116
66. H. Yang, J. Gu, X. Lin, H.B. Grossman, Y. Ye, C.P. Dinney, and et al. Profiling of genetic variations in inflammation pathway genes in relation to bladder cancer predisposition Clin Cancer Res 14 2008 2236 2244